Lifeworks Advisors LLC Decreases Holdings in DaVita Inc. (NYSE:DVA)

Lifeworks Advisors LLC lowered its holdings in shares of DaVita Inc. (NYSE:DVA) by 30.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,866 shares of the company’s stock after selling 832 shares during the period. Lifeworks Advisors LLC’s holdings in DaVita were worth $279,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. FMR LLC grew its stake in shares of DaVita by 659.9% during the third quarter. FMR LLC now owns 177,406 shares of the company’s stock valued at $29,082,000 after buying an additional 154,061 shares during the last quarter. Glenmede Trust Co. NA boosted its holdings in DaVita by 731.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock valued at $20,207,000 after acquiring an additional 108,446 shares during the period. JPMorgan Chase & Co. grew its position in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after acquiring an additional 92,014 shares during the last quarter. KBC Group NV increased its stake in DaVita by 27.3% in the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock worth $51,395,000 after purchasing an additional 67,250 shares during the period. Finally, Strategic Financial Concepts LLC bought a new stake in DaVita in the fourth quarter valued at approximately $9,371,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently commented on DVA. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Barclays boosted their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 18th. Finally, Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, DaVita presently has an average rating of “Hold” and an average price target of $166.33.

DaVita Stock Up 4.5 %

Shares of DaVita stock opened at $146.73 on Friday. The company’s fifty day simple moving average is $159.43 and its two-hundred day simple moving average is $157.90. DaVita Inc. has a 12-month low of $125.64 and a 12-month high of $179.60. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The company has a market cap of $11.74 billion, a P/E ratio of 13.66, a PEG ratio of 1.07 and a beta of 0.99.

DaVita (NYSE:DVA) last released its quarterly earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. Research analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.